A proposal by the Biden Administration to change how prescription drug rebates are calculated in the Medicaid program could have ripple effects that could affect drug pricing and accessibility throughout multiple markets, according to this analysis prepared by the Avalere healthcare consulting and advisory firm and released by HLC.
Proposed Changes to Best Price Could Shift Market Dynamics for Stakeholders
- Topics: Access, Competition, Innovation, Medicaid, Medicare
Related Reports
report
Reducing Fraud, Waste, and Abuse to Improve Healthcare Affordability
HLC convened senior leaders from across the healthcare sector to identify practical, cross-sector ways to reduce fraud, waste, and abuse, with the discussion centered principally on waste and administrative inefficiency. A clear message emerged: hea…
report
Unleashing AI’s Potential for Patients: A Cross-Sectoral Roadmap for Healthcare
A new report from HLC and management consulting and technology firm ZS reveals the risks of today's highly fragmented and inconsistent approach to regulation of AI in the healthcare industry and provides a roadmap of nine practical policy recommenda…
report
Setting the Record Straight: The Facts Behind MedPAC’s Misleading Cost Analysis of Medicare Advantage
Our latest report challenges the accuracy of recent MA spending estimates by MedPAC, exposing critical flaws in the Commission’s revised methodology underpinning its skewed estimates, and calls for greater transparency in evaluating the MA program.
